title: Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.
abstract: Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only a few cases of skin involvement have been reported, primarily in single case reports. We analyzed and present the clinical outcomes, immunohistochemistry and cytogenetic features, and relevant laboratory data on 53 biopsy-proven skin MM cases. The median time from MM diagnosis to skin involvement was 2 years. There appears to be an overrepresentation of immunoglobulin class A (IgA) and light chain disease in skin MM. We found no correlation between CD56 negative MM and skin infiltration. We found that skin MM patients presented in all MM stages (i.e. ISS stages I to III), and there was no preferential cytogenetic abnormality. Patients with skin MM carry a very poor prognosis with a median overall survival (OS) of 8.5 months as time from skin involvement. Moreover, patients with IgA disease and plasmablastic morphology appear to have a worse OS.
authors.affiliation: a Jagiellonian University Medical College , Cracow , Poland ;
authors.forename: Artur
authors.initials: A
authors.lastname: Jurczyszyn
authors.affiliation: b Wroclaw Medical University , Wroclaw , Poland ;
authors.forename: Magdalena
authors.initials: M
authors.lastname: Olszewska-Szopa
authors.affiliation: c Santa Casa Medical School , Sao Paulo , Brazil ;
authors.forename: Vania
authors.initials: V
authors.lastname: Hungria
authors.affiliation: c Santa Casa Medical School , Sao Paulo , Brazil ;
authors.forename: Edvan
authors.initials: E
authors.lastname: Crusoe
authors.affiliation: d University Hospital Olomouc , Olomouc , Czech Republic ;
authors.forename: Tomas
authors.initials: T
authors.lastname: Pika
authors.affiliation: e Department of Hematology University Hospitals Leuven , Belgium ;
authors.forename: Michel
authors.initials: M
authors.lastname: Delforge
authors.affiliation: f Hopital La Miletrie, CHU Poitiers , France ;
authors.forename: Xavier
authors.initials: X
authors.lastname: Leleu
authors.affiliation: g Department of Internal Medicine II , University Hospital Wuerzburg , Wuerzburg , Germany ;
authors.forename: Leo
authors.initials: L
authors.lastname: Rasche
authors.affiliation: h Winship Cancer Institute, Emory University , Atlanta , GA , USA ;
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Nooka
authors.affiliation: i Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Warsaw , Poland ;
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Druzd-Sitek
authors.affiliation: i Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Warsaw , Poland ;
authors.forename: Jan
authors.initials: J
authors.lastname: Walewski
authors.affiliation: j Hospital Universitario De Salamanca , Salamanca , Spain ;
authors.forename: Julio
authors.initials: J
authors.lastname: Davila
authors.affiliation: k Centre Hospitalier Universitaire De Liege , Liege , Belgium ;
authors.forename: Jo
authors.initials: J
authors.lastname: Caers
authors.affiliation: l Department of Medicine - Haematology , Hradec Kralove , Czech Republic ;
authors.forename: Vladimir
authors.initials: V
authors.lastname: Maisnar
authors.affiliation: m Division of Hematology , Mayo Clinic , Rochester , MN , USA ;
authors.forename: Morie
authors.initials: M
authors.lastname: Gertz
authors.affiliation: n Hematology Unit, Department of Onco-Hematology , A.O. of Cosenza , Cosenza , Italy ;
authors.forename: Massimo
authors.initials: M
authors.lastname: Gentile
authors.affiliation: o Hospital Italiano De Buenos Aires , Buenos Aires , Argentina ;
authors.forename: Dorotea
authors.initials: D
authors.lastname: Fantl
authors.affiliation: p Haematology, Ospedale A. Perrino , Brindisi , Italy ;
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mele
authors.affiliation: q John Theurer Cancer Center at Hackensack University Medical Center , Hackensack , NJ , USA ;
authors.forename: David H
authors.initials: DH
authors.lastname: Vesole
authors.affiliation: r Massachusetts General Hospital Cancer Center , Harvard Medical School , Boston , MA , USA ;
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Yee
authors.affiliation: s Royal Victoria Hospital, McGill University , Montreal , Canada ;
authors.forename: Chaim
authors.initials: C
authors.lastname: Shustik
authors.affiliation: t Columbia University Medical Center , New York , NY , USA ;
authors.forename: Suzanne
authors.initials: S
authors.lastname: Lentzsch
authors.affiliation: u VU University Medical Center , Amsterdam , the Netherlands ;
authors.forename: Sonja
authors.initials: S
authors.lastname: Zweegman
authors.affiliation: v Azienda Ospedaliera Universitaria Senese , Siena , Italy ;
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.affiliation: a Jagiellonian University Medical College , Cracow , Poland ;
authors.forename: Aleksander B
authors.initials: AB
authors.lastname: Skotnicki
authors.affiliation: w Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.
authors.forename: Jorge J
authors.initials: JJ
authors.lastname: Castillo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers
keywords: Cutaneous; diagnosis; myeloma; skin; treatment